Design Therapeutics Inc. (DSGN) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Design Therapeutics Inc.

    NASDAQ: DSGN · Real-Time Price · USD
    6.07
    0.11 (1.85%)
    At close: Sep 12, 2025, 1:01 PM

    Design Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 596K 537K 466K 129K
    Gross Profit
    		 -596K -537K -466K -129K
    Operating Income
    		 -62.38M -78.19M -67.59M -35.83M
    Interest Income
    		 12.79M n/a n/a n/a
    Pretax Income
    		 -49.59M -66.86M -63.31M -35.53M
    Net Income
    		 -49.59M -66.86M -63.31M -35.53M
    Selling & General & Admin
    		 18.03M 21.13M 18.98M 11.05M
    Research & Development
    		 44.35M 57.06M 48.61M 24.78M
    Other Expenses
    		 -596K -537K -466K n/a
    Operating Expenses
    		 61.79M 77.65M 67.13M 35.83M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 62.38M 78.19M 67.59M 35.83M
    Income Tax Expense
    		 n/a n/a n/a -107.56K
    Shares Outstanding (Basic)
    		 56.59M 55.98M 55.71M 45.94M
    Shares Outstanding (Diluted)
    		 56.59M 55.98M 55.71M 45.94M
    EPS (Basic)
    		 -0.88 -1.19 -1.14 -0.77
    EPS (Diluted)
    		 -0.88 -1.19 -1.14 -0.77
    EBITDA
    		 -48.99M -66.33M -62.84M -35.7M
    EBIT
    		 -49.59M -66.86M -63.31M -35.53M
    Depreciation & Amortization
    		 596K 537K 466K 129K

    Add to Watchlist